Introduction Non-ST-segment elevation acute coronary syndromes (NSTE-ACS), including
non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable angina, represent a …

Introduction In patients with acute coronary syndrome (ACS), the ischemic benefit of
antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that …

Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual
antiplatelet therapy [DAPT] or dual pathway inhibition [DPI]) are recommended for …

Periprocedural myocardial infarction (PMI) and injury, pertinent to both cardiac and non-
cardiac procedures, have gained increasing recognition in clinical practice. Over time …

Despite evidence-based therapies, patients presenting with atherosclerosis involving more
than one vascular bed, such as those with peripheral artery disease (PAD) and concomitant …

Introduction Dual antiplatelet therapy (DAPT) represents the cornerstone of secondary
prevention in patients presenting with acute coronary syndrome (ACS) and undergoing …

Dual antiplatelet therapy (DAPT), which combines aspirin and a P2Y12 receptor inhibitor, is
commonly recommended after percutaneous coronary intervention (PCI) to prevent ischemic …

Lynaea Filbey from McMaster University in Hamilton, ON, Canada, and colleagues. 1 The
authors note that trials have shaped the way we practise medicine. 2–5 Yet participants …

We thank Lozano et al for their interest in our study on the eligibility to intensified
antithrombotic regimens (ie, prolonged dual antiplatelet therapy [DAPT] and dual pathway …